Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Glioblastoma 6Rectal Neoplasms 5Oropharyngeal Neoplasms 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Burkitt Lymphoma 4Astrocytoma 4Urinary Bladder Neoplasms 3Mouth Neoplasms 3Glioma 3Carcinoma, Squamous Cell 3Adenocarcinoma of Lung 3Rhabdomyosarcoma 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Laryngeal Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Carcinoma 2Breast Carcinoma In Situ 2Adenocarcinoma, Bronchiolo-Alveolar 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1Radiotherapy 1Radiation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Radiotherapy × 30 days × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡